ESTA
Establishment Labs Holdings Inc.74.15
+2.12+2.94%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.15BP/E (TTM)
-Basic EPS (TTM)
-2.84Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Establishment Labs posted solid Q2 FY2025 revenue of $51.3M, up 16.3% y/y from $44.1M and 22.5% q/q (derived) from Q1's $41.4M, fueled by Motiva Implants' U.S. launch post-FDA approval in September 2024, which drove North America's share to 20% of total while EMEA grew 14.4% y/y; gross margin expanded to 68.8% from 65.6% y/y, thanks to higher U.S. pricing. Yet operating expenses surged 29.1% y/y to $49.4M, mainly from SG&A bloat in personnel and marketing, yielding an operating loss of $14.1M, wider than $9.3M last year, and net loss of $16.6M versus $17.2M y/y, with the gap to operating loss under 20% tied to interest and FX gains. Cash dipped to $54.6M from $90.3M year-start amid $39.5M operating burn, offset by $5M short-term debt draw; total debt held steady at $221.1M under the Oaktree facility maturing 2027. In October 2024, closed Motiva Benelux and NL acquisitions for $7.8M (cash/stock/contingent mix), recognizing $0.8M goodwill and $1.5M customer intangibles amortized over 10 years, eyeing European synergies. Competition from bigger players with deeper pockets remains a balanced risk.
8-K
Q2 revenue beats, guidance up
Establishment Labs reported Q2 2025 revenue of $51.3 million, up 16.3% year-over-year, fueled by $10.3 million in US Motiva sales, while gross margins climbed to 68.8% from 65.6% on better geographic mix and pricing. Operating losses widened to $14.1 million amid ramped-up US investments in personnel and marketing, yet adjusted EBITDA loss narrowed to $8.5 million from $4.1 million. The company raised full-year revenue guidance to $208–$212 million, targeting positive EBITDA in 2025. US expansion drives growth, but heavy spending pressures cash.
8-K
Motiva US launch surges
Establishment Labs hosted an investor event on June 12, 2025, updating on Motiva's US launch, with over 1,000 surgeons now offering the implants and Q2 fiscal 2025 sales expected at $9.5 million to $10 million. The company anticipates filing for FDA approval of Motiva for reconstruction in Q4 2025, while planning Preservé's US debut in H1 2026. Motiva's SmoothSilk technology drives lower complications, positioning it for market expansion. Forward-looking estimates carry risks from regulatory and adoption uncertainties.
8-K
Annual meeting elects directors
Establishment Labs shareholders convened their annual meeting on May 23, 2025, electing Juan Jose Chacón Quirós, Ann Custin, Nicholas Lewin, Edward Schutter, and Bryan Slotkin as directors until the 2026 meeting, with strong support exceeding 21 million votes for each. They advisory-approved executive compensation by a wide margin of 21.6 million for versus 56,000 against. The board ratified CBIZ, CPAs P.C. as auditors for fiscal 2025, passing 25.7 million to 38,000. Routine wins signal board stability.
IPO
Employees
Sector
Industry
ABT
Abbott Laboratories
126.86-1.61
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
ELUT
Elutia, Inc.
0.55-0.13
ENOV
Enovis Corporation
26.07-0.47
INMD
InMode Ltd.
14.48+0.15
RMSL
RemSleep Holdings, Inc.
0.00+0.00
TELA
TELA Bio, Inc.
1.18+0.05
VERO
Venus Concept Inc.
2.26+0.59
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52
ZIMV
ZimVie Inc.
18.99+0.00